Do you want to read an article? Please log in or register.
FDA Approval Summary: Fam-trastuzumab deruxtecan-nxki for the treatment of unresectable or metastatic HER2-positive breast cancer
Breast Cancer
Related content
Breast Cancer
Recent Developments in Metastatic Breast Cancer
healthbook TIMES Oncology Hematology
RECOMMENDED
Breast Cancer
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
doi: 10.1016/S1470-2045(20)30112-1.
Breast Cancer
Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results
Breast Cancer Res.
Edith A. PerezEmail, José Manuel López-Vega, Thierry Petit, Claudio Zamagni, Valerie Easton, Julia Kamber, Eleonora Restuccia and Michael Andersson
doi: 10.1186/s13058-016-0773-6
Breast Cancer
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
Lancet Oncol.
Krop IE, Kim SB, Martin AG, LoRusso PM, Ferrero JM, Badovinac-Crnjevic T, Hoersch S, Smitt M, Wildiers H
doi: 10.1016/
RECOMMENDED
Breast Cancer
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Ann Oncol.
Montemurro F, Delaloge S, Barrios CH, Wuerstlein R, Anton A, Brain E, Hatschek T, Kelly CM, Peña-Murillo C, Yilmaz M, Donica M, Ellis P
doi: 10.1016/j.annonc.2020.06.020.
Breast Cancer
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
doi: 10.1056/NEJMoa1914510.
RECOMMENDED
Central Nervous System Tumors
Central Nervous System Metastasis in Patients With HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival From SystHERs
Clin Cancer Res.
Hurvitz SA, O'Shaughnessy J, Mason G, Yardley D, Jahanzeb M, Brufsky AM, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Chu L, Li H, Antao V, Cobleigh M
doi: 10.1158/1078-0432.CCR-
Breast Cancer
First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer
Breast.
Araki K, Fukada I, Yanagi H, Kobayashi K, Shibayama T, Horii R, Takahashi S, Akiyama F, Ohno S, Ito Y
doi: 10.1016/j.breast.2017.06.015.
Breast Cancer
Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials
Clin Cancer Res.
Clavarezza M, Puntoni M, Gennari A, Paleari L, Provinciali N, D'Amico M, DeCensi A
doi: 10.1158/